“We’re preparing for a market that would include additional entrants as the year progresses,” Endo has made clear for its key Vasostrict (vasopressin) 505(b)(2) injectable, following recent genericization of the $900m brand.
Eagle Pharmaceuticals’ ‘at-risk’ launch of the first generic in January this year preceded American Regent’s 505(b)(2) product, as well as...








